drugset / Trial / NCT02260492

Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

NCT02260492

Phase 1 Completed 879 enrolled Oriel Therapeutics
RandomizedParallel-groupQuadruple-blindOther

Summary

This is a study to establish the equivalence of OT329 Solis and Advair Diskus when administered by inhalation in patients with asthma.

Timeline

Start
2014-09
Primary completion
2015-05
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 100 ug Inhaled
Subject salmeterol xinafoate Unknown 50 ug Inhaled

Indications